Rocket Doctor AI joins the B2i Digital Featured Company Program and its Network of more than 1.7 million Retail and Institutional Market Participants

Rocket Doctor AI signs a marketing deal, but offers no numbers or proof of impact.

Risk flags

• ●Execution risk is high because all claimed benefits—marketing campaigns, investor outreach, and US expansion—are forward-looking and lack any evidence of delivery or measurable outcomes. Without clear timelines or performance targets, there is no way to track progress or hold management accountable.
• ●Disclosure risk is significant, as the announcement omits all financial details, including campaign budgets, expected costs, or revenue impact. This lack of transparency prevents investors from assessing the magnitude or materiality of the agreement.
• ●Regulatory risk exists because the agreement is subject to Canadian Securities Exchange approval. If approval is delayed or denied, none of the planned activities can proceed, making the entire announcement contingent and uncertain.

Bottom line

This announcement signals only that Rocket Doctor AI intends to spend on digital marketing through B2i Digital, with all promised benefits remaining hypothetical. No financial details, timelines, or evidence of execution are provided, making it impossible to assess the impact on business value or investor returns. The promotional tone and lack of substance suggest narrative inflation rather than a material event. For investors, this is not actionable without further disclosure of costs, measurable objectives, or evidence of follow-through. The key takeaway: the company is making forward-looking claims without providing the data needed to judge their credibility or significance.

Announcement summary

(CSE: AIDR, OTC: AIRDF) Rocket Doctor AI Inc. has entered into a digital advisory agreement to retain B2i Digital, Inc., a New York corporation, to provide digital marketing advisory services, subject to the approval of the Canadian Securities Exchange. B2i Digital will provide services including building and maintaining a featured company profile on b2idigital.com, creating and managing paid digital advertising campaigns, developing investor-focused content and creative materials, distributing content across social media channels, conducting email marketing campaigns to the investing community, and connecting the Company with relevant investor conferences and speaking opportunities. The agreement is described as a pivotal element of Rocket Doctor AI's strategic initiative to broaden its presence across the US, including New York. Dr. Essam Hamza, CEO of Rocket Doctor AI, stated excitement about being featured in B2i Digital’s program. The promotional activity will be conducted across specified platforms and mediums. The agreement is subject to the approval of the Canadian Securities Exchange. No financial figures, revenue, or specific campaign budgets are disclosed in the announcement.

Disagree with this article?